The Asia-Pacific region is well-placed in the coronavirus disease 2019 (COVID-19) vaccine rollout, with both India and China having sufficient domestic innovation and production capacity to be pivotal vaccine suppliers. Vaccine rollouts in most Asia-Pacific countries will likely extend into 2022 given supply constraints, logistical difficulties, the geographical spread of rural populations, and shortages of trained healthcare professionals. Join Lindsay Newman, Bree Neff, Sophie Cairns, and Deepa Kumar in today's episode as they discuss the geopolitics of the vaccine rollout, vaccine development, and what this means for the recovery timeline. Read more about our vaccine coverage: https://ihsmarkit.com/research-analysis/geopolitical-implications-vaccine-rollout-asia-pacific.html Dr. Lindsay Newman, Director, Economics & Country Risk, IHS Markithttps://ihsmarkit.com/experts/newman-lindsay.html Bree Neff, Director, Economics - Asia Pacific, IHS Markit https://ihsmarkit.com/experts/neff-bree.html Sophie Cairns, Senior Research Analyst, Life Sciences, IHS Markit https://ihsmarkit.com/experts/cairns-sophie.html Deepa Kumar, Senior Analyst – Asia-Pacific Country Risk, IHS Markit https://ihsmarkit.com/experts/kumar-deepa.html

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.